Grant: Project Grant - Priority Announcement: Pediatric Cancer Research
Université Laval
$100,000.00
Understanding the role of beta1 integrins in chemoresistance of acute lymphoblastic leukemia and therapeutic implications
EF 2022-23
Résumé
T cell malignancies are among the fastest rising cancers in North America. For example, T cell-acute lymphoblastic leukemia (T-ALL) accounts for approximately 15% of all childhood leukemia and 25% of all adult leukemia. Although chemotherapy has improved the treatment of T-ALL especially in children, resistance to chemotherapy (chemoresistance or drug resistance) is a major factor in patient relapse and is associated with poor outcome and
significant fatalities. Therefore, a better understanding of how leukemic T-ALL cells manage to escape chemotherapy and become resistant will likely lead to more efficient therapies. We have identified a receptor called alpha2 integrin that is highly expressed in leukemic cells and which can be a critical factor in T-ALL drug resistance and patient relapse. Indeed, when we blocked this receptor, we were able to better eradicate leukemic cells upon their treatment with chemotherapy.
In this proposal, we will characterize the implication of alpha2 integrin in the development of drug resistance of leukemic T-ALL cells and examine the mechanisms by which it does so. We will also determine if the blockade of alpha2 integrin with neutralizing antibodies will enhance the ability of chemotherapy to eradicate patients-leukemic T-ALL cells engrafted in mice. These studies have the potential of revealing a novel therapeutic target in T-ALL. Accordingly, inhibition of alpha2 integrin with existing inhibitors combined with chemotherapy may be a novel strategy for T-ALL therapy to avoid patient relapse and consequently improve clinical outcomes.
Programme
Project Grant - Priority Announcement: Pediatric Cancer Research
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
473367
Name
Aoudjit Fawzi
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics
Projecttitle
Understanding the role of beta1 integrins in chemoresistance of acute lymphoblastic leukemia and therapeutic implications
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Pediatric Cancer Research
Keyworddelim
Cancer Biology; Cell Adhesion; Chemoresistance Mechanisms; Collagen; Flow Cytometry; Integrin Signaling; Leukemia; Molecular And Cell Biology; Patient-Derived Xenografts; Therapeutic Target
Abstract
T cell malignancies are among the fastest rising cancers in North America. For example, T cell-acute lymphoblastic leukemia (T-ALL) accounts for approximately 15% of all childhood leukemia and 25% of all adult leukemia. Although chemotherapy has improved the treatment of T-ALL especially in children, resistance to chemotherapy (chemoresistance or drug resistance) is a major factor in patient relapse and is associated with poor outcome and
significant fatalities. Therefore, a better understanding of how leukemic T-ALL cells manage to escape chemotherapy and become resistant will likely lead to more efficient therapies. We have identified a receptor called alpha2 integrin that is highly expressed in leukemic cells and which can be a critical factor in T-ALL drug resistance and patient relapse. Indeed, when we blocked this receptor, we were able to better eradicate leukemic cells upon their treatment with chemotherapy.
In this proposal, we will characterize the implication of alpha2 integrin in the development of drug resistance of leukemic T-ALL cells and examine the mechanisms by which it does so. We will also determine if the blockade of alpha2 integrin with neutralizing antibodies will enhance the ability of chemotherapy to eradicate patients-leukemic T-ALL cells engrafted in mice. These studies have the potential of revealing a novel therapeutic target in T-ALL. Accordingly, inhibition of alpha2 integrin with existing inhibitors combined with chemotherapy may be a novel strategy for T-ALL therapy to avoid patient relapse and consequently improve clinical outcomes.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Aoudjit, Fawzi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~